Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesylate Apatinib for Stage Ⅳ Soft Tissue Sarcoma Patients After Failure of Traditional Chemotherapy: Prospective, Open-label, Single-Arm, Multi-center Phase II Clinical Trial

Trial Profile

Mesylate Apatinib for Stage Ⅳ Soft Tissue Sarcoma Patients After Failure of Traditional Chemotherapy: Prospective, Open-label, Single-Arm, Multi-center Phase II Clinical Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Alveolar soft part sarcoma; Clear cell sarcoma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Nerve sheath neoplasms; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2019 Results assessing chemotherapy combined with antiangiogenesis drugs in stage IV sarcoma patients using data from NCT03121833 and NCT03121846 studies, presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2019 Results (n=42) assessing efficacy and safety of Apatinib for patients with stage IV soft tissue sarcoma published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019)
    • 19 May 2017 Status changed from not yet recruiting to recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top